

LKL INTERNATIONAL BERHAD (201501014673) (1140005-V) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2024⁽¹⁾

		INDIVIDUAL	QUARTER	CUMULAT	IVE PERIOD
	Note	UNAUDITED CURRENT QUARTER ENDED 30 JUNE 2024 RM'000	UNAUDITED COMPARATIVE QUARTER ENDED 30 JUNE 2023 RM'000	UNAUDITED CUMULATIVE PRECEDING PERIOD TO DATE ENDED 30 JUNE 2024 RM'000	UNAUDITED CUMULATIVE PRECEDING PERIOD TO DATE ENDED 30 JUNE 2023 RM'000
Revenue	A9	9,716	9,451	19,301	19,817
Cost of sales		(7,012)	(5,901)	(14,245)	(12,494)
Gross profit		2,704	3,550	5,056	7,323
Other income		1,232	52	2,396	574
Administrative expenses		(3,232)	(2,594)	(6,420)	(5,075)
Selling and distribution expenses		(612)	(464)	(1,078)	(867)
Other expenses		(2,118)	(8,003)	(8,456)	(9,795)
Net gain / (loss) on impairment of financial assets		167	(27)	(169)	(47)
Share of profit of an associate		-	-	-	-
Loss from operations		(1,859)	(7,486)	(8,671)	(7,887)
Finance costs		(384)	(100)	(799)	(196)
Loss before taxation ("LBT")		(2,243)	(7,586)	(9,470)	(8,083)
Tax expense	В4	(136)	-	(136)	-
Loss after taxation ("LAT")		(2,379)	(7,586)	(9,606)	(8,083)
Other comprehensive income		-	-	-	-
Total comprehensive income/(expense) for the financial period		(2,379)	(7,586)	(9,606)	(8,083)
Total comprehensive income/(expense) for the financial period attributable to:- Owners of the Company Non-controlling interests		(2,389) 10 (2,379)	(7,584) (2) (7,586)	(9,621) 15 (9,606)	(8,080) (3) (8,083)
Loss per share (sen) - Basic ⁽²⁾	B11	(0.62)	(3.12)	(2.48)	(3.23)

Notes:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Profit or loss and Other Comprehensive Income is detailed in Note A1 and should be read in conjunction with the audited financial statements for the financial year ended ("FYE") 31 December 2023 and the accompanying explanatory notes attached to this interim financial report.
- (2) Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue.

1



LKL INTERNATIONAL BERHAD (201501014673) (1140005-V) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 30 JUNE 2024 $^{(1)}$

	Note	UNAUDITED AS AT 30 JUNE 2024 RM'000	AUDITED AS AT 31 DECEMBER 2023 RM'000
ASSETS			
Non-current Assets			
Property, plant and equipment		85,836	74,029
Right-of-use assets		3,333	3,832
Investment in quoted shares		35,229	38,015
		124,398	115,876
Current Assets			
Inventories		17,293	16,620
Trade receivables		10,462	11,977
Other receivables, deposits and prepayments		14,065	21,884
Amount owing by a related party		228	228
Other investment		-	5,202
Fixed deposit with licensed bank		20,681	20,380
Cash and bank balances		4,548	10,988
		67,277	87,279
Assets included in disposal group classified as held for sale		-	11,811
6		67,277	99,090
TOTAL ASSETS		191,675	214,966
EQUITY AND LIABILITIES			
Equity			
Share capital		240,262	240,262
Merger deficit		(29,580)	(29,580)
Accumulated losses		(48,642)	(39,021)
Equity attributable to owners of the Company		162,040	171,661
Non-controlling interests		(623)	(638)
TOTAL EQUITY		161,417	171,023
Non-current Liabilities			
Lease liabilities	B8	1,696	2,050
Bank borrowings	B8	6,521	6,616
		8,217	8,666
Current Liabilities Trade payables		1,115	338
Other payables and accruals		4,041	10,462
Bank borrowings	В8	15,363	22,131
Lease liabilities	B8	932	1,208
Current tax liabilities	БО	590	-
Provision for taxation		-	1,138
		22,041	35,277
TOTAL LIABILITIES		30,258	43,943
TOTAL EQUITY AND LIABILITIES		191,675	214,966
Net asset per share (RM) (2)		0.42	0.44

Notes:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Financial Position is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FYE 31 December 2023 and the accompanying explanatory notes attached to this interim financial report.
- (2) Net asset per share is calculated based on the number of ordinary shares in issue of 388,057,256 shares.



LKL INTERNATIONAL BERHAD (201501014673) (1140005-V)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2024⁽¹⁾

<----> Attributable to Equity Holders of the Company <-----> Accumulated **Total Attributable to** Non-controlling **Share Capital** Merger Deficit Losses **Owners of Company** Interests **Total Equity** RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 240,262 (29,580)(39,021)171,661 (638)171,023 Balance at 1 January 2024 **Transactions with owners** Ordinary shares issued pursuant to: - Right issue with warrants - Share issuance expenses Disposal of shares to non-controlling interest Loss and other comprehensive expense for the financial period (9,621)(9,621)15 (9,606)Balance at 30 June 2024 240,262 (29,580)(48,642) 162,040 (623) 161,417

Note:-

⁽¹⁾ The basis of preparation of the Unaudited Condensed Consolidated Statements of Financial Position is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FYE 31 December 2023 and the accompanying explanatory notes attached to this interim financial report.



LKL INTERNATIONAL BERHAD (201501014673) (1140005-V)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2024 $^{\left(1\right)}$

Page		UNAUDITED PERIOD ENDED 30 JUNE 2024 RM'000	UNAUDITED PERIOD ENDED 30 JUNE 2023 RM'000
loss before taxations (9,4%) (8,88) Algoistments for 2,108 97 Depreciation of property, plant and equipment (1,745) 1,75 Gain on adgoard of property, plant and equipment (1,765) 1,75 Gain on adgoard of right of use asset (3,76) 1,75 Gain on adgoard of right of use asset (3,76) 1,77 Interest for white does not necessary the contract of written does not nivertonics 31 1 Net reversal of written does not nivertonics 1,61 4 Net reversal of written does not nivertonics in under receivables 1,69 9,00 Net reversal of written does not nivertonics in under the receivables 1,69 9,00 Pair value loss on more the receivables 1,69 9,00 Fair value loss on tronger exchange 40 1,70 Pair value loss on tronger exchange 40 1,70 Fair value loss on tronger exchange 40 1,20 Privalue gain on investment in other investment on the investment on the change in inventories 1,20 2,71 Privalue gain on investment in other investment on the privale change in inventories 1,20<	CASH FLOWS FROM OPERATING ACTIVITIES	NW 600	KIVI 000
Depreciation of property, plant and equipment		(9,470)	(8,083)
Gain on disposal of property, plant and equipment (1,745) (17) 1 Caper calculation of right of use assets 588 376 Line or strong or right of use assets 588 326 Interest expense 330 327 Interest income 31 - Reversal of miniment or son other receivables 10 90 Not receivable for interest or written down on inventionies 109 900 Not impairment loss on trade receivables 109 900 Fair value loss on interestment in quited shares (38) - Fair value loss on interestment in quited shares (38) - Fair value loss on interestment in quited shares (1,129) - Fair value loss on interestment in other investment (38) - Fair value loss on interestment in other investment (38) - Fair value loss on interestment in other investment (38) - Fair value loss on interestment in other investment (38) - Fair value loss on interestment in other investment (1,104) - Increased/screase in in writer and the pre	Adjustments for:		
Gain on disposal of right of use assets 568 376 Interest supense 835 256 Interest supense 335 256 Interest supense 1 (268) Reversal of annual leave 1 2 Reversal of annual leave 150 4 Reversal of impairment loss on other receivables 150 4 Reversal of impairment loss on their receivables 150 4 Reversal of impairment loss on their receivables 150 4 Rei value gain on investment in other investment 138 - Fair value gain on investment in other investment 188 - Unrealized gain on foreign exchange (10,12) 2,112 Increase/decrease in trade and other receivables 2,00 (11,12) Increase (are xpaid 2,00 (2,78) Income tax paid (709) (11,20) Income tax paid (709) (12,38) Income tax paid (20,08) (20,78) Income tax paid (20,08) (20,78) Income tax paid (20			
Depreciation of ingit-of-use assets 588 375 Interest income (320) (377) Reversal of minul leave (320) (377) Reversal of imminiment loss on univertories 31 - 6 Net reversal of imminiment loss on univertories 19 9,000 Net representation of imminiment loss on univertories 169 9,000 Fair value loss on investment in other investment (38) - 7 Fair value loss on foreign exclusing (46) - 12 Fair value loss on foreign exclusing (40) - 12 Fair value loss on foreign exclusing (5,64) - 2,122 Operating foor) / profit before working capital changes (1,102) - 2,122 Correcase in trade and other receivables 9,209 (26,734) Decrease in trade and other receivables 9,209 (26,734) Correcase in trade and other receivables 9,209 (26,734) Correcase in trade and other provides 30 37 37 Cost BLOWS FROM INVESTING ACTIVITIES 1,387 1,20 2,21 Cost H. LOWS FROM INVESTING ACTIVITIES		• • • • • • • • • • • • • • • • • • • •	(15)
Interest repense 835 256 1675			- 576
Interest Comme (370) (277) (278) (
Net reversal of written down on inventories			
Reversal of impairment loss on other receivables 160 9,000 Fair value loss on investment in quoted shares 3(8) 3(8) Fair value loss on investment in quoted shares 3(8) 3(8) Fair value loss on investment in develoe investment 3(8) -1 Fair value gain on foreign exchange 4(9) -1 Fair value gain on investment in develoe investment 3(8) -1 Fair value gain on investment in develoe investment 3(8) -1 Fair value gain on investment in develoe investment 3(10) -1 Fair value gain on investment in develoe investment 3(10) -1 Fair value gain on investment in develoe investment 3(10) -1 Fair value gain on investment in develoe investment 3(10) -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other receivables -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of an other previous -1 -1 Fair value gain of previous -1 -1 Fair value gain value -1 -1 Fair value gain	Reversal of annual leave	-	(268)
Net impairment loss on trade receivables 169 9,000 167 1		31	-
Fair value loss on investment in quoted shares 6,786 (3) Fair value loss on investment in on the investment (38) - Cheralised gain on foreign exchange (65) - Operating (loss) / profit before working capital changes (1,129) 2,131 Increase/decrease in inventories (706) (1,040) Increase/decrease in trade and other receivables 5,5644 (2,234) CASH LOSED IN OPERATIONS 1,730 (27,960) Income to a paid (709) 1,312 Income to a paid (709) 1,321 Interest received 2,02 2,77 RECASH USED IN OPERATING ACTIVITIES 360 (2,048) CASH ELOWS FROM INVESTING ACTIVITIES 2 (2,088) (2,004) Acquisition of investment in quoted shares (2,098) (2,004) Acquisition of investment in quoted shares 38 - Acquisition of investment in quoted shares 38 - Acquisition of injett-of-use asset 1,4 (5,174) Proceeds from disposal of property, plant and equipment 1,74 (3,28) <td></td> <td>-</td> <td></td>		-	
Fair value gain on investment in other investment	·		
Processing loss of profit before working capital changes			(5)
Cross Cros			-
Decrease in trade and other receivables	Operating (loss) / profit before working capital changes	(1,129)	2,112
Decrease in trade and other receivables	Increase/decrease in inventories	(706)	(1.104)
Decrease in trade and other payables (5,644) (2,23d) CASH LUSD IN OPERATIONS 1,730 (27,960) Income tax paid (709) (13) Income tax refunded 26 1,382 Income tax refunded 320 377 NET CASH USED IN OPERATING ACTIVITIES 320 377 CASH PLOWS FROM INVESTING ACTIVITIES (2,098) (2,004) Acquisition of property, plant and equipment (2,098) (2,008) Acquisition of investment in outer investments 38 - Acquisition of investment in other investments 38 - Acquisition of inject-of-use asset 1,740 15 Proceds from disposal of property, plant and equipment 1,740 15 Pros Basic carrings/(loss) per share is calculated based on the number of ordinary shares in issue 163 328 Net CASH USED IN NVESTING ACTIVITIES 2,804 Net T CASH USED IN NVESTING ACTIVITIES 1 48,567 Net T CASH USED IN NVESTING ACTIVITIES 1 48,567 Net T CASH USED IN NVESTING ACTIVITIES 1 48,564 Net T C	·	, ,	
Comme tax paid (709) (13) (13) (130)			, , ,
Incented tax refunded 26 1,382 Interest recived 320 377 NET CASH USED IN OPERATING ACTIVITIES 1,367 0,2014 CASH FLOWS FROM INVESTING ACTIVITIES C. (2,098) (2,004) Acquisition of property, plant and equipment (2,098) (2,004) Acquisition of investment in other investments 38	CASH USED IN OPERATIONS	1,730	(27,960)
NET CASH USED IN OPERATING ACTIVITIES 1,367 1,26	Income tax paid	(709)	(13)
NET CASH USED IN OPERATING ACTIVITIES 1,367 (26,211) CASH FLOWS FROM INVESTING ACTIVITIES 2,000 (2,000) Acquisition of investment in quoted shares (4,000) (10,775) Acquisition of investment in other investments 38 - Acquisition of injeth-of-use asset (4) (5,17) Proce Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 2,80 NET CASH SED IN INVESTING ACTIVITIES - 2,80 NET DECKSH SED IN INVESTING ACTIVITIES - 2,80 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,56			
CASH FLOWS FROM INVESTING ACTIVITIES 2,098 (2,008) Acquisition of property, plant and equipment (2,008) (2,004) Acquisition of investment in quoted shares (4,000) (10,775) Acquisition of investment in other investments 38 - Acquisition of injeth-of-use asset (4) (517) Proceeds from disposal of property, plant and equipment 1,740 15 Proceeds from disposal of property, plant and equipment 1 40 Termination adjustment of right-of-use asset 163 328 MET CASH USED IN INVESTING ACTIVITIES (4,161) 12,913 CASH FLOWS FROM FINANCING ACTIVITIES - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of them purchase (65) (1,663) Repayment of them loans (66) (1,663) Repayment of them loans (66) (1,663) Repayment of them loans (66) (2,614) NET CASH AGENERATE FROM FINANCING ACTIVITIES			
Acquisition of property, plant and equipment (2,008) (2,004) Acquisition of investment in other investments 38 - Acquisition of injet-of-use asset (4) (517) Proceeds from disposal of property, plant and equipment 1,740 15 Proceeds from disposal of property, plant and equipment 1,740 15 Proceeds from disposal of property, plant and equipment 163 328 Termination adjustment of right-of-use asset 163 328 MET CASH USED IN INVESTING ACTIVITIES 163 328 NET CASH SUBLIN INVESTING ACTIVITIES 2 2,804 NET CASH USED IN INVESTING ACTIVITIES 1 48,567 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of line purchase 285 - Repayment of term loans (665) (1,663) Repayment of term loans (665) (1,667) Repayment of term loans (4,34) 9,983 NET CASH GENERATED FROM FINANCING ACTIVITIES (4,34) 9,983 NET CASH GENERATED FROM FINANCING ACTIVITIES (4,34) </td <td>NET CASH USED IN OPERATING ACTIVITIES</td> <td>1,367</td> <td>(26,214)</td>	NET CASH USED IN OPERATING ACTIVITIES	1,367	(26,214)
Acquisition of investment in quoted shares (4,000) (10,775) Acquisition of investment in other investments 38 - Acquisition of injeth-of-use asset (4) (517) Proceds from disposal of property, plant and equipment 1,740 15 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue 163 328 NET CASH USED IN INVESTING ACTIVITIES 163 328 CASH FLOWS FROM FINANCING ACTIVITIES - 2,804 Provedous from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (665) (1,663) Repayment of term loans (665) (1,663) Repayment of term loans (665) (2,600) Repayment of trem loans (665) (2,600) Repayment of term loans (665) (2,601) NET CASH GENERATED FROM FINANCING ACTIVITIES (3,00) 49,101 NET CASH GENERATED FROM FINANCING ACTIVITIES (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALA			
Acquisition of investment in other investments 38			
Acquisition of right-of-use asset (4) (517) Proceeds from disposal of property, plant and equipment 1,740 15 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Termination adjustment of right-of-use asset 163 328 NET CASH USED IN INVESTING ACTIVITIES - 2,804 CASH FLOWS FROM FINANCING ACTIVITIES - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of tire purchase (665) (1,63) Repayment of term loans (665) (1,63) Repayment of term loans (665) (1,63) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,603) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE (4,394) 9,983 CASH AND CASH EQUIVALENTS AT EGINNING OF THE FINANCIAL PERIO			(10,775)
Proceeds from disposal of property, plant and equipment 1,740 15 Proc Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Termination adjustment of right-of-use asset 163 328 NET CASH USED IN INVESTING ACTIVITIES (4,161) (12,913) CASH FLOWS FROM FINANCING ACTIVITIES - 2,804 Drawdown of bankers' acceptances - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of bankers' acceptances (17 - Repayment of bankers' acceptances 177 - Repayment of bankers' acceptances (17 - Repayment of bankers' acceptances 17 - Repayment of bankers' acceptances (17 - Repayment of bankers' acceptances 17 - NET CASH GENERATED FROM FINANCING ACTIVITIES (4,949) 9,983 EFFECTS OF FOREIGN EXCHADGE RATE CHANGES ON THE BALANC	·		- (517)
Pror Basic earnings/(loss) per share is calculated based on the number of ordinary shares in issue - 40 Termination adjustment of right-of-use asset 163 328 NET CASH USED IN INVESTING ACTIVITIES (4,161) (12,913) CASH FLOWS FROM FINANCING ACTIVITIES - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of bankers' acceptances (665) (1,663) Repayment of bankers' acceptances 177 - Repayment of bankers' acceptances (665) (1,663) Repayment of bankers' acceptances (665) (1,663) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE (1,600) 49,110 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254			, ,
NET CASH USED IN INVESTING ACTIVITIES (4,161) (12,913) CASH FLOWS FROM FINANCING ACTIVITIES 3 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 (665) Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT ERGINNING OF THE FINANCIAL PERIOD 12,305 37,254 Cash and dash equivalents at end of the financial period comprise the following: 2 2 Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft		-	
CASH FLOWS FROM FINANCING ACTIVITIES Drawdown of bankers' acceptances - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of ine purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: 2 2 Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) -		163	328
Drawdown of bankers' acceptances - 2,804 Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 CASH HELD IN FOREIGN CURRENCIES 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 16,698 26,708 Cash and cash equivalents at end of the financial period comprise the following: 20,681 20,058 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft 12,305 37,254 Less: Fixed deposit pledged with a licensed bank	NET CASH USED IN INVESTING ACTIVITIES	(4,161)	(12,913)
Net proceeds from issuance of ordinary shares via right issue with warrants (1) 48,567 Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,633) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGES ON THE BALANCE 1 563 CASH AND CASH EQUIVALENTS AT EGGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT ERGINNING OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - -	CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of hire purchase 285 - Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: 4,548 17,196 Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft 12,924 - Less: Fixed deposit pledged with a licensed bank - -	Drawdown of bankers' acceptances	-	
Repayment of lease liabilities (1,136) (347) Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) Less: Fixed deposit pledged with a licensed bank - -			48,567
Repayment of term loans (665) (1,663) Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 OF CASH HLD IN FOREIGN CURRENCIES 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - - Less: Fixed deposit pledged with a licensed bank - -			- (247)
Repayment of bankers' acceptances 177 - Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE 1 563 OF CASH HELD IN FOREIGN CURRENCIES 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - -	• •		
Interest paid (260) (251) NET CASH GENERATED FROM FINANCING ACTIVITIES (1,600) 49,110 NET DECREASE IN CASH AND CASH EQUIVALENTS (4,394) 9,983 EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - L	, ,	, ,	-
NET DECREASE IN CASH AND CASH EQUIVALENTS EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD Cash and cash equivalents at end of the financial period comprise the following: Cash and bank balances Fixed deposit with a licensed bank Bank overdraft Less: Fixed deposit pledged with a licensed bank		(260)	(251)
FFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD Cash and cash equivalents at end of the financial period comprise the following: Cash and bank balances Fixed deposit with a licensed bank Bank overdraft Cash and cash equivalents at end of the financial period comprise the following: 17,196 11,296 12,305 37,254 12,305 37,254 12,305 37,254 12,305 37,254	NET CASH GENERATED FROM FINANCING ACTIVITIES	(1,600)	49,110
FFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD Cash and cash equivalents at end of the financial period comprise the following: Cash and bank balances Fixed deposit with a licensed bank Bank overdraft Cash and cash equivalents at end of the financial period comprise the following: 17,196 11,296 12,305 37,254 12,305 37,254 12,305 37,254 12,305 37,254			
OF CASH HELD IN FOREIGN CURRENCIES 1 563 CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: V Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft 12,305 37,254 Less: Fixed deposit pledged with a licensed bank - -		(4,394)	9,983
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD 16,698 26,708 CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: V Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft 12,924 - Less: Fixed deposit pledged with a licensed bank - -		4	500
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD 12,305 37,254 Cash and cash equivalents at end of the financial period comprise the following: 4,548 17,196 Cash and bank balances 20,681 20,058 Fixed deposit with a licensed bank (12,924) - Bank overdraft 12,305 37,254 Less: Fixed deposit pledged with a licensed bank - -			
Cash and cash equivalents at end of the financial period comprise the following:Cash and bank balances4,54817,196Fixed deposit with a licensed bank20,68120,058Bank overdraft(12,924)-Less: Fixed deposit pledged with a licensed bank			
Cash and bank balances 4,548 17,196 Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - -			<u> </u>
Fixed deposit with a licensed bank 20,681 20,058 Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - -		Λ 5ΛΩ	17 104
Bank overdraft (12,924) - Less: Fixed deposit pledged with a licensed bank - -			
Less: Fixed deposit pledged with a licensed bank 12,305 37,254	·		-
			37,254
12,305 37,254	Less: Fixed deposit pledged with a licensed bank		
		12,305	37,254

Note:-

⁽¹⁾ The basis of preparation of the Unaudited Condensed Consolidated Statements of Cash Flows is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FYE 31 December 2023 and the accompanying explanatory notes attached to this interim financial report.



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The interim financial report of LKL International Berhad ("**LKL International**" or "**the Company**") and its subsidiaries ("**the Group**") is unaudited and has been prepared in accordance with the requirements of MFRS 134 - Interim Financial Reporting issued by the Malaysian Accounting Standard Board ("**MASB**"), Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("**Bursa Securities**").

The interim financial report should be read in conjunction with the audited financial statements for the financial year ended 31 December 2023 ("FYE 2023"). These explanatory notes attached to the interim financial report provide explanation of events and transactions that are significant for the understanding of the changes in the financial position and performance of the Group since the FYE 2023.

A2. Changes in accounting policies

The Group has adopted those standards and interpretations (including the consequential amendments, if any) that have become effective on 1 January 2023 and such adoptions do not have material impact on the financial position and performance of the Group.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the MASB are effective for this interim financial report: -

		Effective Date
Amendments to MFRS 16:	Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101:	Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants	1 January 2024
Amendments to MFRS 107 and MFRS 7:	Supplier Finance Arrangement	1 January 2024
Amendments to MFRS 121: Amendments to MFRS 10 and	Lack on Exchangeability	1 January 2025
MFRS 128:	Sales or Contribution of Assets between an Investor and	Deferred until
	its Associate or Joint Venture	further notice

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) is expected to have no material impact on the interim financial report of the Group upon its initial application.

A3. Auditors' report on preceding audited financial statements

The preceding year's audited financial statements of the Group were not subject to any qualification.

A4. Seasonal or cyclical factors

The Group's business operations were not materially affected by seasonal or cyclical factors during the current financial quarter under review.



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and current period-to-date under review except as disclosed in the unaudited financial statements.

A6. Material changes in estimates

There were no changes in estimates that have had a material effect in the current financial quarter under review.

A7. Debts and equity securities

There was no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

A8. Dividend paid

There was no dividend paid during the current financial quarter under review.

A9. Segmental information

(a) Analysis of revenue by product categories

, ,	In	UNAU DIVIDUA	DITED L QUARTER			C	UNAU UMULATI	DITED VE PERIOD	
	30 JUNE	2024	30 JUNI	2023		30 JUNE 2024		30 JUNE 2023	
	RM'000	%	RM'000	%		RM'000	%	RM'000	%
Manufacturing:									
Medical/healthcare									
beds	1,598	16.45	2,594	27.45		3,811	19.75	4,732	23.88
Medical peripherals									
and accessories	4,419	45.48	5,221	55.24		7,546	39.09	10,433	52.65
	6,017	61.93	7,815	82.69		11,357	58.84	15,165	76.53
Trading:									
Medical peripherals									
and accessories	2,951	30.36	1,568	16.59		6,581	34.10	4,511	22.76
Medical devices	46	0.48	7	0.08		63	0.33	12	0.06
•	2,997	30.84	1,575	16.67		6,644	34.43	4,523	22.82
Retail:									
Healthcare and									
Pharmaceuticals	702	7.23	61	0.64		1,300	6.73	129	0.65
Total revenue	9,716	100.00	9,451	100.00	_	19,301	100.00	19,817	100.00



EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM A. FINANCIAL REPORTING (CONT'D)

A9. Segmental information (Cont'd)

(b) Analysis of revenue by geographical areas

	II	UNAU IDIVIDUA	DITED L QUARTER			С	UNAU UMULATI	DITED VE PERIOD	
	30 JUNE	2024	30 JUNE	E 2023		30 JUNE	2024	30 JUNE 2023	
	RM'000	%	RM'000	%		RM'000	%	RM'000	%
Local:									
Malaysia	8,436	86.83	8,457	89.48		16,827	87.18	17,688	89.26
Export:									
Africa	4	0.04	281	2.97		884	4.58	449	2.26
Asia - other than									
Malaysia	751	7.73	682	7.22		1,058	5.48	1,480	7.47
Europe	524	0.01	-	-		525	2.72	55	0.28
Middle East	1	5.39	31	0.33		7	0.04	145	0.73
	1,280	13.17	994	10.52		2,474	12.82	2,129	10.74
Total revenue	9,716	100.00	9,451	100.00	_	19,301	100.00	19,817	100.00

A10. Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment for the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There were no other material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. **Changes in composition of the Group**

There were no material changes in the composition of the Group for the current financial quarter under review.

A13. Contingent assets or contingent liabilities

The Group has no other contingent assets and contingent liabilities as at the date of this report except for the following:

a)	Contingent	t lia	bili	ties
----	------------	-------	------	------

Contingent habilities	UNAUDITED AS AT 30 JUNE 2024 RM'000	AUDITED AS AT 31 DECEMBER 2023 RM'000
Bank guarantees given by financial institution to third parties	434	786



A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A14. Capital commitments

	UNAUDITED AS AT	AUDITED AS AT
	30 JUNE	31 DECEMBER
	2024	2023
	RM'000	RM'000
Approved and contracted for:		
Purchase of property, plant and equipment	23,464	39,599

A15. Related party transactions

Significant related party transactions for the financial period to date are as follows :

RM'000

Transactions with a company in which the major shareholder of the Company, Bioalpha Holding Berhad has substantial interests:

Mediconstant Pharmacy Sdn. Bhd.

-	Outlets management fee paid	252
-	Promotion and marketing fee paid	-
-	Manpower related paid	268
-	Shoplot sublease rent & utilities related paid	294
-	Purchase of pharmaceutical products, medical,	
	healthcare equipment and pharmacy related.	1,047

Transactions with a company in which a director of the Company, Datuk Chong Loong Men has substantial interests: Parlo Tours Sdn. Bhd.

- Purchase of travel services including airline ticket and hotel bookings ______53



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES

B1. Review of performance of 6-month ended 30 June 2024 ("2Q 2024")

The Group's performance for the 2Q 2024 is as tabled below:

	UNAUDITED 2Q 2024 RM'000	UNAUDITED 2Q 2023 RM'000
Revenue	19,301	19,817
Gross profit	5,056	7,323
Loss Before Tax ("LBT")	(9,470)	(8,083)

Q2 FY2024 vs Q2 FY2023

For the current quarter ended 30 June 2024 (Q2FY24), the Group registered a lower revenue of RM19.301 million, a marginal decrease of RM0.516 million or 2.6% from the corresponding quarter in the preceding year (Q2FY23).

The Group posted revenue of RM19.301 million mainly contributed by the orders delivered from the manufacturing segment of medical/ healthcare beds, medical peripherals and accessories. Geographically, the local market remains as the largest revenue contributor at RM16.827 million or 87.18% of the group revenue where the remaining revenue of RM2.474 million or 12.82% of the group revenue was generated from exports, mainly from another Asian region for the 2Q 2024.

The Group reported a gross profit of RM5.056 million and a gross profit margin of 26.20% for the current financial period. In Q2FY23, the Group reported a gross profit of RM7.323 million and gross profit margin of 36.95%. It shows that the gross profit margin reduces 10.75% mainly due to higher material cost and loss from pharmacy operations.

The Group posted a LBT of RM9.470 million (Q2FY23: RM 8.083 million) for the current financial period mainly due to losses in the fair value on investment in quoted shares of RM6.786 million (Q2FY23: RM 9.000 million), depreciation and lease expense of RM2.677 (Q2FY23: RM 1.556 million) million and interest expense of RM0.798 million (Q2FY23: RM 0.196 million).

Manufacturing Segment

The manufacturing segment of medical/healthcare beds, medical peripherals and accessories delivered orders totaling RM11.357 million or 58.84% of the group revenue for the current financial period mainly to the orders received from the government and private healthcare centers.

This segment posted a gross profit of RM4.105 million and a gross profit margin of 36.15% for the current financial period on the back of certain medical beds and peripherals sold at better profit margins. Consequently, this segment registered an operating loss of RM 0.760 million due to higher depreciation and interest expense as disclosed above.

Trading Segment

The trading segment of medical peripherals, accessories and medical devices contributed RM6.644 million or 34.43% of group revenue for the current financial period. This segment posted a gross profit of RM1.687 million and a gross profit margin of 25.35%.

Consequently, this segment posted an operating profit of RM0.888 million from the operations before interest and tax expenses for the current financial period.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B1. Review of performance of 6-month ended 30 June 2024 ("2Q 2024") (Cont'd)

Pharmacy Retail Segment

The revenue contributed from the pharmacy retail segment improved to RM1.293 million for the current financial period with seven pharmacy outlets located in the major cities in Klang Valley, represent 6.73% of the group revenue for the current financial period.

Due to the lower sales volume resulting from poor pricing power and stiff competition, this segment registered a gross loss of RM0.735 million for the current financial period, and consequently, this segment posted an operating loss of RM1.589 million before interest and tax mainly due to reasons stated above.

Investment Holding Segment

This segment continues to register a loss on fair value of the quoted investments of RM6.786 million resulting in an operating loss of RM7.211 million for this segment for the current financial period.

B2. Comparison with preceding quarter's results

	UNAUDITED CURRENT QUARTER ENDED 30 JUNE 2024 RM'000	UNAUDITED PRECEDING QUARTER ENDED 31 MARCH 2024 RM'000
Revenue	9,716	9,585
Gross profit	2,704	3,773
Loss Before Tax ("LBT")	(2,243)	(7,227)

Q2 FY2024 vs Q1 FY2024

Revenue for the current quarter increased by RM 0.131 million or 1.37% as compared to the preceding quarter (Q1FY24) mainly due to the due to increased sales of medical peripherals in the current quarter.

The Group registered a loss before tax of RM2.243 million in the current financial quarter as compared to a loss before tax of RM7.227 million in Q1 2024 mainly due to a higher fair value loss of RM 5.224 million recorded in the previous quarter.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B3. Prospects

Malaysia's economy recorded an encouraging growth of 4.2% in Q1 2024, surpassing economic analysts' median projection of 3.9%. The growth momentum extended beyond Gross Domestic Product (GDP). Malaysia's economy has expanded at the fastest rate in six quarter for Q2 2024. The Q2 GDP was expected to expand 5.8% based on advance estimates released by the Department of Statistics Malaysia (DOSM). This would be the highest quarterly growth recorded since Q4 2022 which stood at 7.4%.

According to DOSM, Malaysia saw its leading index (LI) grow 3.8% year-on-year to 114.2 points in May 2024, from 110.0 points in the same period last year. Malaysia's LI has maintained its positive growth for the six consecutive months, primarily supported by a sturdy gain in the Bursa Malaysia Industrial Index (up 31.8%), followed by real imports of other basic precious and other non-ferrous metals (up 20.6%).

The tariff hike by the United States on imports from China may divert trade and increase foreign direct investment in Malaysia benefiting our economy. HLIB Research pointed out that imports from Malaysia to the US grew at a five-year compound annual growth rate of 7.7% during the US enacting tariffs on China, whereby the foreign composition of total approved investments rose from 26% to 59% over the trade war period.

According to CIMB Research, Malaysia's economy remained on target, with GDP growth likely to reach the upper-end of Bank Negara Malaysia's (BNM) projection of 4% to 5% for 2024. The robust growth would likely be aided by the country's resilient labour market and household spending, ongoing multi-year investments, higher foreign direct investment realisation, trade recovery and improving tourism. The fiscal reform by the government, efforts in containing inflation and the high-level investments approved as well as the policies to stabilise and develop the country will also support the economy and the ringgit.

While anticipating gradual growth in Malaysia's overall industrial production and forecasting a rise in the sales volume in the year 2024, the Group remains vigilant to the uncertainty and continues to take active steps to mitigate any foreseeable risks on the business. With the evolving trends of businesses, we will continue to focus on our core competencies, seize new opportunities through innovation and exploring new markets by diversifying our products and services.

The Group believes that diversification into the pharmacy business, which has a favourable outlook due to the increased public health awareness, will spur the business segment and subsequently contribute to long-term stable income streams. The Group has a total of seven pharmacy outlets including six new pharmacy outlets, namely Constant Pharmacy to serve the community of the major areas in Klang Valley. Looking forward, the Group is also in the process of acquiring additional 3 strategic pharmacy outlets. This expansion plan will improve our pricing power immediately as a result of more volumes generated from more outlets.

The local currency rose 0.6% to 4.5922 against the dollar late July. After falling to a 26-year low in February, the Malaysian currency has done a complete turnaround to become Asia's best performer this year. Analysts expect Malaysia's economy to continue its growth momentum after Q2 GDP beat all estimates. Nevertheless, the Group will remain vigilant and proactively monitor the volatility of foreign exchange rates as part of our risk mitigation plan.

In the early month of July 2024, the Monetary Policy Committee of BNM has decided to maintain the Overnight Policy Rate at 3.00%. The global economy continues to expand amid resilient labour markets and continued recovery in global trade. Looking ahead, global growth is expected to be sustained, as headwinds from tight monetary policy and reduced fiscal support will be cushioned by positive labour market conditions and moderating inflation.

July saw a moderation in the Malaysian manufacturing sector as demand conditions remained muted, according to S&P Global Market Intelligence. The seasonally adjusted S&P Global Malaysia manufacturing purchasing managers' index dipped slightly to 49.7 in July from 49.9 in June. Purchasing activity, stocks of inputs and inventories of finished goods were all scaled back at the start of the third quarter, though only stocks of purchases saw the rate of moderation quicken on the month. Inflationary pressures remained prevalent among Malaysian manufacturers meanwhile, as input price inflation edged slightly up to reach the highest for eight months.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B3. Prospects (Cont'd)

Despite all the challenges and difficulties faced by the Group, we are committed to ensuring the Group's long-term growth by continuously exploring and pursuing available opportunities that are prospective in increasing shareholders' value. Looking ahead, the Group strives to improve the sales volume by expanding and offering a wider variety of medical devices to our customers.

The Group continues to leverage its long-term strategic relationships with the existing and potential business associates and partners that would improve the business process efficiency and cost-effectiveness. The Group also continues to pursue progress in its joint venture arrangements to meet its objectives.

Broadening our distributorship scope, we believe the existing engagement with SECA and MEDITOP's products enables us to further introduce more medical devices to the market. We strive to build a more resilient organisation, upholding operational efficiencies and sustainable initiatives to navigate through business challenges, thereby reinforcing our position as a reliable, one-stop solutions provider to the medical and healthcare industry.

B4. Tax expense

	UNAUDITED INDIVIDUAL QUARTER ENDED 30 JUNE 2024 RM'000	UNAUDITED INDIVIDUAL QUARTER ENDED 30 JUNE 2023 RM'000	UNAUDITED CUMULATIVE PERIOD ENDED 30 JUNE 2024 RM'000	UNAUDITED CUMULATIVE PERIOD ENDED 30 JUNE 2023 RM'000
Current tax expense Under provision in prior	136	-	136	-
financial period	-	-	-	-
	136		136	

There was no tax expense during the quarter in view of the unabsorbed tax losses.

B5. Variance of actual profit from profit forecast and profit guarantee

The Group has not issued any profit forecast or profit guarantee in any form of public documentation and announcement during the current financial quarter under review.

B6. Status of corporate proposals

There were no corporate proposals announced but not completed as at the date of this report.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B7. Utilisations of proceeds from corporate exercises

a) Pursuant to the Right Issue with Warrants, the details of the issuance of Right Shares as at the date of this report are as follows:

Issuance Date	No. of Shares	Issue Price (RM)	Total Proceeds (RM)
28 March 2023	290,897,202	0.17	49,452,524

The status of utilisation of proceeds as at 30 June 2024:

	Purposes	Proceeds raised RM'000	Actual utilisation RM'000	Deviation RM'000	Unutilised proceeds RM'000	Estimated timeframe for utilisation
(a)	Expansion of the pharmacy business	48,353	24,476	206	24,083	Within 24 months
(b)	Estimated expenses in relation to the Proposals	1,100	894	(206)	-	Immediate
	Total	49,453	25,370	-	24,083	

Note:-

B8. Group's borrowings and debt securities

The Group's borrowings as at 30 June 2024 were as follows:

	UNAUDITED AS AT	AUDITED AS AT	
	30 JUNE	31 DECEMBER	
	2024	2023	
	RM'000	RM'000	
Current:			
Bank overdraft	12,924	19,873	
Bankers' acceptance	2,238	2,061	
Lease liabilities	932	1,208	
Term loans	201_	197	
	16,295	23,339	
Non-current:	_		
Lease liabilities	1,696	2,050	
Term loans	6,521	6,616	
	8,217	8,666	
Total borrowings:			
Bank overdraft	12,924	19,873	
Bankers' acceptance	2,238	2,061	
Lease liabilities	2,628	3,258	
Term loans	6,722	6,813	
	24,512	32,005	

All the borrowings were secured and denominated in Ringgit Malaysia.

⁽¹⁾ In view that the actual listing expenses were less than estimated, the surplus has been re-allocated for expansion of the pharmacy business.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B9. Material litigation

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report.

(i) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. (WA-24NCC(ARB)-37-12/2020)

On 16 December 2020, LKL Advance Metaltech Sdn. Bhd. ("LKLAM") had through its solicitors, Messrs. Chong + Kheng Hoe, filed an Originating Summons in the High Court in Kuala Lumpur bearing registration number: WA24NCC(ARB)-37-12/2020 ("OS") against Crecom Burj Gloves Sdn. Bhd. ("Defendant").

The High Court had on 5 March 2021 granted a Mareva injunction to freeze the Defendant's asset up to the amount of RM12,542,784 after hearing all parties involved. The Defendant has been wound up on 29 September 2022.

The Defendant's liquidator had on 20 September 2023 filed an application to set aside the Mareva injunction. Parties had on 6 November 2023 recorded a consent order to set aside the Mareva injunction on the condition that, amongst others, the Defendant's liquidator accept and admit the Plaintiff's Proof of Debt lodged with the Defendant's liquidator.

In line with the OS, LKLAM had also filed a Notice of Arbitration dated 11 January 2021 ("Arbitration") against the Defendant. LKLAM claims against the Defendant for breach of the Purchase Agreement dated 2 October 2020 which was entered into by both parties for the purchase of gloves from the Defendant. In the Arbitration, LKLAM is seeking from the Defendant the sum of RM12,542,784, general damages, interest, costs and any further relief that the arbitral tribunal thinks fit and just.

The Defendant filed a Response to the Arbitration dated 16 February 2021 counterclaiming for the sum of RM20,374,500 for the purported balance amount due to the Defendant. The Arbitration is pending appointment of arbitrator by the director of Asian International Arbitration Centre. There was no progress in the case as at the date of this report.

(ii) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. and 6 others (WA-22NCC-331-07/2021)

On 26 July 2021, LKLAM had through its solicitors, Messrs Chong + Kheng Hoe, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur bearing suit number: WA-22NCC-331-07/2021 ("Suit") against Crecom Burj Gloves Sdn. Bhd., Crecom Burj Group Sdn. Bhd., Datin Roslinda Binti Jaafar, Khairil Anuar Bin A. Rahman, Nurul Ashikin Binti Muhammad Muhiyuddin, Chew Seng Ker and Nurul Balqis Binti Khairul Anuar ("Defendant").

LKLAM is claiming against Defendants for the return of RM12,540,757 being payment made by LKLAM for the purchase of gloves from Crecom Burj Group Sdn. Bhd. pursuant to the purchase agreement dated 2 October 2020.

On 23 August 2022, the second Defendant, Crecom Burj Group Sdn. Bhd. has been wound up by the Kuala Lumpur High Court. LKLAM has filed a post-winding up suit no. WA-28PW-620-12/2022 to obtain leave from the Kuala Lumpur High Court to continue the proceeding against the second Defendant, Crecom Burj Group Sdn. Bhd. in suit WA-22NCC-331-07/2021.

On 29 September 2022, the first Defendant, Crecom Burj Gloves Sdn. Bhd. has been wound up by the Shah Alam High Court. LKLAM has filed a post-winding up suit no. BA-28PW-314-12/2022 to obtain leave from the Shah Alam High Court to continue the proceeding against the first Defendant, Crecom Burj Gloves Sdn. Bhd. in suit WA22NCC-331-07/2021.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B9. Material litigation (Cont'd)

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report (Cont'd)

(ii) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. and 6 others (WA-22NCC-331-07/2021)

The initial trial dates on 20 to 24 May 2024 has been vacated as 3 of the Defendants, Datin Roslinda Binti Jaafar, Khairil Anuar Bin A. Rahman and Nurul Balqis Binti Khairul Anuar had been declared bankrupt and has yet to be discharged as of to-date. To proceed with the 3 defendants thereof, a leave to continue the proceeding against the bankrupts must be obtained ("Leave to Continue Proceeding").

The Court has subsequently fixed a date for case management on 29 August 2024 for the aforementioned defendants to obtain sanction from the Insolvency Department and for LKLAM to update the Court on the status of Leave to Continue Proceeding. The new trial dates are fixed on 28 July to 1 August 2025.

(iii) LKL Advance Metaltech Sdn. Bhd. vs Genesis Gateway Sdn. Bhd. (WA-28NCC-800-11/2021)

On 8 November 2021, LKLAM ("Petitioner") has had through its solicitors, Messrs. Chong + Kheng Hoe, presented a Winding Up Petition at the Kuala Lumpur High Court registered under Companies (Winding-Up) No. WA-28NCC-800-11/2021 against Genesis Gateway Sdn Bhd ("Respondent") for the sum of RM13,311,960.96, indebted by the Respondent to the Petitioner wherein the Petitioner is seeking inter alia for the Respondent to be wound up by the Court and the incidental reliefs related thereto. The Court has also appointed a liquidator of the Respondent and Petitioner has filed their proof of debt to the liquidator on 31 October 2022.

(iv) LKL International Berhad vs The Edge Communications Sdn. Bhd. (WA-23NCvC-50-05/2021)

On 25 May 2021, the Company had through its solicitors, Messrs. Wong Kian Kheong, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur against The Edge Communications Sdn. Bhd. ("The Edge"). The suit was initiated against The Edge for the article published at pages 62 to 64 of "The Edge Malaysia" on 12 April 2021 entitled "Hidden hands behind penny stock surge under scrutiny" ("Article"), of which the Company alleged that certain words in the Article were defamatory of LKL International Berhad.

The Company is seeking from The Edge, amongst others, damages and an injunction to restrain The Edge whether by itself, its agents or servants or otherwise from publishing or causing to be published the same or similar words defamatory of the LKL International.

On 19 August 2021, the Edge filed a striking out application to strike out the Company's claim, and the High Court has on 17 May 2022 dismissed The Edge's striking application with costs in the cause. The Court has vacated the trail scheduled on 15 to 17 January 2024. The matter is fixed for trial on 18 November 2024 and 19 November 2024.

B10. Dividend proposed

There was no dividend proposed for the current financial quarter under review.



B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B11. Loss per share ("LPS")

The basic LPS for the current financial quarter and financial period-to-date are computed as follows:

	UNAUDITED INDIVIDUAL QUARTER ENDED 30 JUNE 2024	UNAUDITED INDIVIDUAL QUARTER ENDED 30 JUNE 2023	UNAUDITED CUMULATIVE PERIOD ENDED 30 JUNE 2024	UNAUDITED CUMULATIVE PERIOD ENDED 30 JUNE 2023
Net profit/(loss) attributable to ordinary equity holders of the Company (RM'000)	(1,982)	(7,584)	(9,621)	(8,080)
Weighted average number of ordinary shares in issue ('000)	388,057	243.412	388,057	249,841
Basic LPS (Sen)	(0.51)	(3.12)	(2.48)	(3.23)

B12. Notes to the Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income

PBT or LBT is arrived at after charging/(crediting):

	UNAUDI	ITED	UNAU	UNAUDITED		
	INDIVIDUAL QUA	ARTER ENDED	CUMULATIVE PERIOD ENDED			
	30 JUNE 30 JUNE		30 JUNE	30 JUNE		
	2024	2023	2024	2023		
	RM'000	RM'000	RM'000	RM'000		
Depreciation of property, plant and						
equipment	780	490	2,108	979		
Gain on disposal of property, plant and						
equipment	(988)	-	(1,745)	(15)		
Depreciation of right-of-use assets	140	331	568	576		
Interest expense	420	137	835	256		
Interest income	(154)	(243)	(320)	(377)		
Net written down on inventories	31	(374)	31	(268)		
Impairment loss/(gain) on trade	(167)	27	169	47		
receivables	(107)	21	109	47		
Fair value loss on investment						
in quoted shares	1,600	7,574	6,786	9,000		
Unrealised loss/(gain) on foreign	(2)	267	(46)	(3)		
exchange	(2)	207	(40)	(5)		

Other disclosure items pursuant to Appendix 9B Note 16 of the ACE Market Listing Requirements of Bursa Securities are not applicable.

B13. Authorisation for Issue

The interim financial report was authorised for issue by the Board of Directors on 28 August 2024.